"Patients with glioblastoma have a median survival of twelve to eighteen months, despite surgery, radiation and chemotherapy. The glioblastoma cancer cells are also very resistant to the traditional therapies of radiation and chemotherapy; tumors tend to aggressively recur after these treatments. Therefore, new treatment approaches are needed."
The px866 tPhase II trial started in Jan 2011 on a planned 30 "incurable" patients that have already relapsed and the trial is looking to see how these incurable patients respond to px 866 in terms of tate of progression.
This is a tough business they are in. This kind of trial is an ultimate test of the theory behind PX 866. It is not being used in a combo trial with another drug like some of the others. The PI3K inhibitor is the theory being tested. will it work? some results apparenty being resported at asco.
I seem to recall Kirkman saying something about "stable" patients in a cc. The life exptency of people that have failed other treatment can't be very long. Yup, it's a tough business they are in and the goals are not easy to fight these incurable diseases. But they keep on keeping on n trying.
that's what's kept me long over 20 years in tears in a nutshell. They keep on keeping on.
and why haven't they just thrown in the towel on blp25 after start failed anyway?
I seem to recall in a presentation earlier this month Kirkman said ASCO was "gonna be big for us this year". Is he normally overzealous or can we expect some good data? If so, this stock should move higher.
Kirkman can't ever get exuberant until they actually deliver somethng. He's gotta stay balanced and seems to be well aware not to be seen as a pumper cause that can come back in ways that they don;'t want. after stimuvax that's just the way it is. but px 866 is his baby as is all the past px compounds that went nowhere. PX 866 is supposed to be the best of the best though/
covalent bonding et al.